当前位置：
X-MOL 学术
›
Signal Transduct. Target Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Signal Transduction and Targeted Therapy ( IF 40.8 ) Pub Date : 2019-12-17 , DOI: 10.1038/s41392-019-0099-9 Min Yuan 1, 2 , Li-Li Huang 1, 2 , Jian-Hua Chen 1, 3 , Jie Wu 3, 4 , Qing Xu 1, 2
Signal Transduction and Targeted Therapy ( IF 40.8 ) Pub Date : 2019-12-17 , DOI: 10.1038/s41392-019-0099-9 Min Yuan 1, 2 , Li-Li Huang 1, 2 , Jian-Hua Chen 1, 3 , Jie Wu 3, 4 , Qing Xu 1, 2
Affiliation
|
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
中文翻译：
非小细胞肺癌靶向治疗的新兴治疗前景。
肺癌是世界上最常见的癌症之一。2018年，肺癌新发病例超过200万例，肺癌死亡人数超过170万人。靶向治疗已成为非小细胞肺癌（NSCLC）患者疾病管理的重要手段。在此，我们回顾和分析最近的文献，讨论肺癌的靶向途径和正在进行的临床试验。化疗不再是所有患者的最佳治疗方法。治疗决策应以了解患者肿瘤组织的分子特征为指导。未来的成果可能来自于寻找结合靶向治疗、免疫治疗和化疗的最佳方法。
更新日期：2019-12-17
中文翻译：
非小细胞肺癌靶向治疗的新兴治疗前景。
肺癌是世界上最常见的癌症之一。2018年，肺癌新发病例超过200万例，肺癌死亡人数超过170万人。靶向治疗已成为非小细胞肺癌（NSCLC）患者疾病管理的重要手段。在此，我们回顾和分析最近的文献，讨论肺癌的靶向途径和正在进行的临床试验。化疗不再是所有患者的最佳治疗方法。治疗决策应以了解患者肿瘤组织的分子特征为指导。未来的成果可能来自于寻找结合靶向治疗、免疫治疗和化疗的最佳方法。
京公网安备 11010802027423号